Richard Eisenstadt
2017 - Neos Therapeutics
In 2017, Richard Eisenstadt earned a total compensation of $704.9K as Chief Financial Officer at Neos Therapeutics, a 4% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $65,728 |
|---|---|
| Option Awards | $180,883 |
| Salary | $339,771 |
| Stock Awards | $105,000 |
| Other | $13,522 |
| Total | $704,904 |
Eisenstadt received $339.8K in salary, accounting for 48% of the total pay in 2017.
Eisenstadt also received $65.7K in non-equity incentive plan, $180.9K in option awards, $105K in stock awards and $13.5K in other compensation.
Rankings
In 2017, Richard Eisenstadt's compensation ranked 10,582nd out of 14,666 executives tracked by ExecPay. In other words, Eisenstadt earned more than 27.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,582 out of 14,666 | 28th |
Division Manufacturing | 4,114 out of 5,768 | 29th |
Major group Chemicals And Allied Products | 1,465 out of 2,074 | 29th |
Industry group Drugs | 1,196 out of 1,730 | 31st |
Industry Pharmaceutical Preparations | 929 out of 1,329 | 30th |
Source: SEC filing on April 30, 2018.
Eisenstadt's colleagues
We found two more compensation records of executives who worked with Richard Eisenstadt at Neos Therapeutics in 2017.
News
PharmAthene CEO Vipin Garg's 2022 pay rises 9% to $2.9M
August 16, 2023
PharmAthene CEO Vipin Garg's 2021 pay jumps 83% to $2.6M
August 16, 2022
AYTU BIOPHARMA CEO Joshua Disbrow's 2021 pay jumps 291% to $6.2M
April 7, 2022
Neos Therapeutics CEO Gerald McLaughlin's 2019 pay falls 56% to $1.4M
April 21, 2020
Neos Therapeutics CEO Gerald McLaughlin receives $3.2M in 2018
April 24, 2019